Physician profile
David E Rosow
NPI 1467619973
$4,393.94
in general payments reported to CMS, 2019-2025
21 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2022: $3,520 · 2023: $55.21 · 2024: $322 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,519.90 | 2022 | |
| Karl Storz Endoscopy-America | $167.76 | 2019 | |
| Olympus America INC. | $155.27 | 2024 | Rhino-Laryngo Fiberscope, Olympus |
| Astrazeneca Pharmaceuticals LP | $85.03 | 2024-2025 | Lynparza |
| C2dx, INC | $55.21 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.84 | 2025 | |
| Sobi, INC | $36.35 | 2025 | |
| Taiho Oncology, INC. | $35.42 | 2025 | |
| Merck Sharp & Dohme LLC | $30.22 | 2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $28.87 | 2024 | |
| Immunocore Limited | $28.56 | 2025 | Kimmtrak |
| Incyte Corporation | $26.93 | 2025 | Monjuvi, Zynyz |
| Deciphera Pharmaceuticals INC. | $26.75 | 2025 | Qinlock, Romvimza |
| Celgene Corporation | $25.39 | 2019 | |
| Servier Pharmaceuticals LLC | $24.94 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $24.89 | 2025 | Cabometyx |
| Genentech USA, INC. | $20.33 | 2024 | Columvi, Lunsumio, Polivy |
| Janssen Biotech, INC. | $15.85 | 2025 | Rybrevant |
| Jazz Pharmaceuticals INC. | $14.98 | 2024 | |
| Genzyme Corporation | $14.30 | 2024 | |
| Eisai INC. | $14.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.